Peristat test featured on CBS TV news - Watch It here.

Download the Microsoft Windows Media Player

November 15th, 2006

Los Angeles, California – The Peristat Group launches new service for home-based Macular Degeneration (AMD) testing. Following the successful introduction of its first automated technology for online glaucoma testing, the Peristat Group launches a follow-on service for the screening and remote monitoring of AMD. The new technology enables doctors and their patients with dry and wet AMD, as well as people at risk for macular degeneration, to monitor retinal function and disease progression over the internet. Through a subscription service with www.keepyoursight.com, people can access the new test called Macustat online from their home. The system “turns” the home computer into a diagnostic station and for less than 10 minutes the test creates a functional “scan” of the retina to detect even the slightest abnormalities and changes related to AMD. This unprecedented service enables highly reliable and precise diagnostics for best-in-class care. Both patients and doctors can stay in control even outside the office and between appointments. Macustat received FDA clearance earlier this year. More than 1 million people have Wet AMD and over 10 million have Dry AMD in the US. Since there is no pain involved, the symptoms of AMD appear late, once vision is lost. With routine testing every week or every month, keepyoursight.com ensures the best odds against two of the leading causes of blindness – glaucoma and AMD. Peristat delivers the future of telemedicine today!

February 1, 2006

Los Angeles, California – The Peristat Group and Lighthouse International announce partnership and joint online vision drive. Lighthouse International, dedicated to helping people of all ages overcome the challenges of vision loss, and Peristat®, a disease management company committed to public health and sight preservation, have partnered to introduce the Peristat Perimetry System, the first and only clinically validated glaucoma screening self-test to receive FDA clearance. The online system is a virtual telemedicine device which delivers a 3 minute test accessible to anyone with a computer and an internet connection via links from VisionConnection (www.visionconnection.org), Lighthouse’s interactive website with the latest information on vision impairment and its prevention. Peristat’s telemedicine system is the only virtual device to receive FDA clearance for disease screening online. More than 50% of the people with glaucoma are currently undiagnosed, with nearly 2 million people in the US and 40 million in the world foregoing timely and sight-saving treatment.

August 1, 2005

Los Angeles, California – The Peristat Group and AllABoutVision.com announce online partnership to increase awareness against glaucoma and provide telemedicine service for screening and prevention. With this agreement, AllAboutVision – an online consumer portal for vision and eye health information, will offer Peristat’s glaucoma screening service to its users. This is a unique partnership which will allow direct consumer access to first-in-class, clinical-grade technology for independent home testing. Peristat’s telemedicine system is the only virtual device to receive FDA clearance for disease screening online. More than 50% of the people with glaucoma are currently undiagnosed, with nearly 2 million people in the US and 40 million in the world foregoing timely and sight-saving treatment.

Los Angeles, California - Peristat Group, LLC announces Vision Drive, a public health and charitable program. Peristat Group, LLC, the maker of this site, announced Vision Drive, a major public health initiative. Vision Drive will allow 5000 people to test their visual field with Peristat on-line test for only $2. The company will donate all proceeds from this event to charity to benefit those less fortunate individuals who suffer from glaucoma.

November 15, 2004

Los Angeles, California - Peristat test featured on CBS TV news. Today CBS2 - Los Angeles featured the Peristat test in the HealthBeat section of the daily news. A complete recording of the broadcast, including an interview with Dr. Sean Ianchulev, MD, MPH, is available here.

Download the Microsoft Windows Media Player

April 2004

Barcelona, Spain - The International Perimetric Society has selected Peristat to present its research at the annual meeting in Barcelona. IPS is the academic forum that features the latest advances in visual field testing and glaucoma diagnosis. After the demonstration of its perimetry system in the US, the Peristat Group has received considerable attention form both industry and academia for its glaucoma screening technology. The Peristat system provides a much needed solution in the efforts for cost-effective screening of glaucoma, and is currently undergoing final pilot testing before its scheduled launch in June 2004.

November 2003

Los Angeles, California - The Peristat test receives clearance with the FDA as an automated perimetry device for visual field analysis. Peristat is the only FDA-registered clinically-validated virtual perimetry for patient self-testing and glaucoma screening. The system is a product of years of clinical research and investigation by physicians and scientists who bring together the latest advances in ophthalmology and information technology.

April 2003

Ft. Lauderdale, Florida - The Peristat group was invited to present the results of its clinical trial at the annual meeting of the Association for Research in Vision and Ophthalmology. The clinical investigation conducted at USC reports the efficacy of the test for the detection of moderate to severe visual field defects from glaucoma. The study compared the Peristat test to standard office perimetry in patients diagnosed with glaucoma. Virtual perimetry correlates closely with in-office testing and achieves 85-90% accuracy for scotoma detection.

February 2002

Los Angeles, California - Peristat received the Nesburn Award for best research in ophthalmology. The research team from the University of Southern California was credited for the development of the first clinically validated virtual perimetry system for the screening and prevention of glaucoma. Glaucoma is a silent disease that affects more than 2 million people in the US. More than half are undiagnosed due to the lack of a cost-effective screening system, and many more find out about their disease too late in its course to benefit from timely treatment. The Peristat is a new test that allows patients to check their peripheral vision for subtle changes related to glaucoma in much the same way eye doctors do with expensive medical equipment in their offices.